Experimental drug shown to 'significantly' slow progression of brain cancer
A new experimental drug was found to "significantly" reduce the progression of brain cancer, Reuters reported.
Vorasidenib, created by Servier Group, a private drug developer, was shown to slow the progression of brain tumors by an average of over 16 months, per Bloomberg. The results of the 331-patient study were published June 4 in The New England Journal of Medicine.
The study's lead author, Ingo Mellinghoff, described this as "a very big finding," adding that the drug "is the first molecularly targeted treatment for diffuse glioma." Vorasidenib specifically works on Grade 2 gliomas, which are "progressive, malignant brain tumors" that are "more common in adults but can also occur in children and teenagers," according to Reuters. The drug blocks a specific enzyme mutated in low-grade gliomas, keeping them from progressing and postponing the need for further treatment like chemotherapy.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"What you just heard is a trial that was well done and well thought out: to use an oral, targeted, well-tolerated therapy to see if we could delay the use of our standard chemotherapy and radiation," Wake Forest Baptist Health's Dr. Glenn Lesser commented at an American Society of Clinical Oncology briefing. "The results are quite striking and they're statistically highly significant, and more importantly, they're clinically very, very significant."
Servier Group is working to get the drug approved by the Food & Drug Administration for use in the U.S.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
Aid to Ukraine: too little, too late?
Talking Point House of Representatives finally 'met the moment' but some say it came too late
By The Week UK Published
-
5 generously funny cartoons on the $60 billion foreign aid package
Cartoons Artists take on Republican opposition, aid to Ukraine, and more
By The Week US Published
-
Knife: Salman Rushdie's 'mesmeric memoir' of brutal attack
The Week Recommends The author's account of ordeal which cost him his eye is both 'scary and heartwarming'
By The Week Staff Published
-
Immunotherapy and hay fever
The Explainer Research shows that the treatment could provide significant relief from symptoms for many hay fever sufferers
By Richard Windsor, The Week UK Published
-
Bird flu worries mount as virus found in milk, cows
Speed Read The FDA found traces of the virus in pasteurized grocery store milk
By Peter Weber, The Week US Published
-
Lead poisoning remains a threat
The Explainer The toxin is built into our lives
By Devika Rao, The Week US Published
-
The best health care systems in the world
In the spotlight Getting sick has never felt better
By Devika Rao, The Week US Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
The alarming rise of cancer in young people
Under the radar Cancer rates are rising, and the cause is not clear
By Devika Rao, The Week US Published
-
How happy is Finland really?
Today's Big Question Nordic nation tops global happiness survey for seventh year in a row with 'focus on contentment over joy'
By Harriet Marsden, The Week UK Published